Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company whose news flow centers on rare neuroendocrine diseases and MC4R pathway–targeted therapies. The company’s updates frequently highlight global commercial performance of its lead product IMCIVREE (setmelanotide), regulatory milestones, and clinical data across multiple rare obesity indications.
Investors following RYTM news can expect regular announcements on net product revenues from global sales of IMCIVREE, including the relative contributions from the United States and international markets. Rhythm also issues press releases on reimbursement developments, such as public reimbursement agreements for IMCIVREE in Canadian provinces and under federal programs for patients with Bardet-Biedl syndrome–related obesity.
Clinical and regulatory news is a major focus. Rhythm reports on Phase 3 trials like TRANSCEND in acquired hypothalamic obesity and EMANATE in genetically caused MC4R pathway diseases, as well as exploratory and Phase 2 studies in Prader-Willi syndrome and other rare conditions. Updates often include topline efficacy and safety data, cardiometabolic outcomes, and patient- and caregiver‑reported measures presented at scientific meetings.
Regulatory communications include FDA actions on supplemental New Drug Applications, PDUFA goal dates and extensions, and EMA validation of Type II variations to existing marketing authorizations. Rhythm also provides information on development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism.
For users tracking RYTM, this news feed offers a centralized view of earnings releases, clinical trial readouts, regulatory decisions and access milestones related to IMCIVREE and Rhythm’s broader rare disease pipeline.
Rhythm Pharmaceuticals (RYTM) has scheduled a conference call and webcast for April 7, 2025, at 8:00 a.m. ET to present topline results from their Pivotal Phase 3 TRANSCEND trial. The trial evaluates setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
The biopharmaceutical company, which focuses on rare neuroendocrine diseases, will make the webcast available under the 'Events and Presentations' section of their investor relations website. The recording will remain accessible for at least 30 days after the call.
Rhythm Pharmaceuticals (RYTM) has announced the reacquisition of rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau through the termination of its 2021 licensing agreement with RareStone Group The company will repay $6.3 million in cash to RareStone and return all previously acquired RareStone shares without additional consideration.
The reacquisition aligns with Rhythm's strategy to develop setmelanotide and next-generation MC4R agonists globally. The company's global trial of setmelanotide in patients with acquired hypothalamic obesity is progressing as planned, with topline data expected in Q2 2025. The trial is currently being conducted across North America, Europe, and Japan.
Rhythm Pharmaceuticals (RYTM) has received orphan drug designation from Japan's Ministry of Health for setmelanotide, targeting acquired hypothalamic obesity treatment. Setmelanotide, an MC4R agonist designed to treat hyperphagia and obesity, is currently being evaluated in a global Phase 3 trial with topline data expected in Q2 2025.
The designation highlights the significant unmet medical need in Japan, where an estimated 5,000 to 8,000 patients live with acquired hypothalamic obesity. The condition affects approximately 5,000-10,000 people in the U.S. and 3,500-10,000 in the E.U. This rare disease typically occurs following hypothalamic injury from brain tumors, traumatic brain injury, stroke, or inflammation.
The orphan designation in both Japan and Europe positions Rhythm to potentially deliver the first-ever treatment targeting the underlying biology of hypothalamic obesity, pending successful Phase 3 trial results and regulatory approvals.
Rhythm Pharmaceuticals (RYTM) and the Raymond A. Wood Foundation have announced a research collaboration to study the impact of fatigue in people with craniopharyngioma. The initiative involves a registry study open to all diagnosed patients and their caregivers.
The study aims to investigate fatigue effects related to craniopharyngiomas and explore factors like weight gain and daytime sleepiness that may influence patient experiences. Participants can enroll through the Hypothalamic-Pituitary Brain Tumors Patient Registry at the foundation's website.
Rhythm Pharmaceuticals (RYTM) reported Q4 2024 global sales of $41.8 million for IMCIVREE, up 26% from Q3 2024. Full-year 2024 revenue reached $130.1 million, compared to $77.4 million in 2023.
Key developments include FDA approval for IMCIVREE's expanded label to treat children as young as 2 years old, and completion of enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon. The company raised $75 million through ATM equity offering, extending cash runway into 2027.
Financial results show Q4 2024 net loss of $44.6 million ($0.72 per share). R&D expenses increased to $238.0 million for 2024, while SG&A expenses reached $144.3 million. Cash position as of December 31, 2024, was $320.6 million.
Rhythm Pharmaceuticals (RYTM), a global commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, has scheduled two important investor events. The company will host a conference call and webcast on February 26, 2025, at 8:00 a.m. ET to discuss its fourth quarter and full year 2024 financial results and provide a corporate update.
Additionally, CEO David Meeker will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 1:10 p.m. ET. Both events will be available via webcast on the company's investor relations website, with recordings accessible for 30 days following each event.
Rhythm Pharmaceuticals (RYTM), a commercial-stage biopharmaceutical company specializing in rare neuroendocrine diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. David Meeker, M.D., who serves as Chair, President and Chief Executive Officer, will engage in a fireside chat on Wednesday, February 12, 2025, at 8:40 a.m. ET.
The presentation will be accessible via webcast in the Investor Relations section of Rhythm's website under 'Events & Presentations' at www.rhythmtx.com. Interested parties can access a replay of the webcast on the company's website for 30 days following the presentation.
Rhythm Pharmaceuticals (RYTM) announced preliminary Q4 2024 net revenues of approximately $42 million from global IMCIVREE sales, up 26% from Q3 2024, and full-year 2024 revenues of approximately $130 million compared to $77.4 million in 2023. U.S. sales contributed about 74% of Q4 and 73% of full-year revenues.
The company reported several pipeline developments: completion of enrollment in the Japanese cohort of Phase 3 trial for acquired hypothalamic obesity (HO), with topline data expected in H1 2025; completion of enrollment in two substudies of Phase 3 EMANATE trial for MC4R pathway diseases; and plans to initiate a new Phase 2 trial for Prader-Willi syndrome in Q1 2025. The company is also advancing trials for bivamelagon and RM-718 in HO treatment.
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced FDA approval for expanded indication of IMCIVREE® (setmelanotide) to treat children as young as 2 years old with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed POMC, PCSK1, and LEPR deficiencies. IMCIVREE is the first precision medicine targeting MC4R pathway impairment, addressing hyperphagia and obesity in these rare conditions.
The approval follows successful clinical trials showing significant weight and hunger reduction. The drug was previously approved for patients 6 years and older, and has received marketing authorization in the UK and EU for patients as young as 2 years. BBS affects approximately 4,000-5,000 people in the US, while POMC, PCSK1, and LEPR deficiency obesities affect 600-2,500 people.
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced that the UK's MHRA has expanded marketing authorization for IMCIVREE (setmelanotide) to treat obesity and control hunger in patients as young as 2 years old with Bardet-Biedl syndrome (BBS) or POMC, PCSK1, or LEPR deficiency. Previously approved for patients 6 years and older in 2022, IMCIVREE received NICE recommendation for NHS reimbursement in May 2024 for BBS patients aged 6-17. The drug will be available through the Medicines for Children program by year-end. A similar application is under FDA priority review with a PDUFA date of December 26, 2024.